



## **Silence Therapeutics to Present at Rodman and Renshaw's 5<sup>th</sup> Annual Global Healthcare Conference**

**London – 6 May 2008 – Silence Therapeutics plc** (AIM: SLN), a leading European RNA interference (RNAi) focused biotechnology company, today announced that CEO Jeff Vick, will present a corporate overview at *Rodman and Renshaw's 5<sup>th</sup> Annual Global Healthcare Conference*. The conference takes place May 19 - 20, 2008 at Le Meridien Beach Plaza Hotel at the Sea Club in Monte Carlo, Monaco.

During his presentation, Mr. Vick will provide updates on Silence's two partnerships with AstraZeneca. Silence's first AstraZeneca partnership is in RNAi therapeutic discovery and development, and the second is in the development of a range of novel approaches for the delivery of siRNA molecules. Mr. Vick's presentation will also feature the Company's AtuRNAi<sup>®</sup> therapeutic development programmes, including Atu027, an AtuRNAi clinical candidate in development for cancer, as well as AtuPLEX<sup>®</sup>, Silence's proprietary, functional liposomal systemic drug delivery system. Functional systemic delivery is widely believed to be a critical component in realising the exciting potential of RNAi therapeutics to treat a broad range of diseases, and based on preclinical results, AtuPLEX is expected to be an important systemic siRNA delivery technology.

Mr. Vick's presentation will take place on Tuesday, May 20, at 2:00 p.m. CET in the Atlantique Salon-Western (second floor) and he will be available for one-on-one meetings during the conference. His presentation will be webcast and available live and for replay at <http://www.wsw.com/webcast/rrshq13/sln.in>. For more information, please visit <http://www.rodmanandrenshaw.com/conferences?id=18>

Enquiries:

For further information, please contact the following:

**Silence Therapeutics plc**  
+44(0)20 7307 1620  
Jeff Vick, Chief Executive Officer  
Melvyn Davies, Finance Director & Company Secretary

**European Contacts:**  
**Citigate Dewe Rogerson**  
+44(0)20 7638 9571  
David Dible  
Emma Palmer  
Heather Keohane

**U.S. Contacts:**  
**LaVoie Group**  
+1 – 978.745.4200  
Bryan Murphy x 105  
Tim Allison x 102

**Notes to Editors:**

**About Silence Therapeutics plc ([www.silence-therapeutics.com](http://www.silence-therapeutics.com))**

Silence Therapeutics plc (AIM: SLN) is a leading European RNAi focused biotechnology company. RNAi can selectively 'silence' genes linked to the onset of disease. RNAi is a Nobel Prize winning technology and one of the most promising areas of drug discovery and development today.

Silence Therapeutics has developed a platform of novel short interfering RNA ('siRNA') molecules, AtuRNAi, which provide a number of advantages over conventional siRNA molecules, including increased stability against nuclease degradation. In addition, the Company has developed a proprietary systemic delivery system, AtuPLEX. This system enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake.

Silence's lead internal product, Atu027, is a proprietary AtuRNAi molecule in preclinical development for systemic cancer indications. Atu027 has successfully completed single and repeat dose toxicology and geno-toxicology studies, as well as a 28-day toxicology study using multiple dosing regimens. Silence plans a regulatory filing in 2008 to commence clinical trials for Atu027.

In March of 2008 Silence Therapeutics announced a collaboration with AstraZeneca (LSE: AZN) focused on the development of a range of novel delivery approaches for siRNA molecules. Under the terms of the agreement both Silence Therapeutics and AstraZeneca will be allowed to commercialize the truly novel delivery systems that the two partners develop together.

In July 2007, Silence Therapeutics formed its first research and development collaboration with AstraZeneca to develop novel AtuRNAi therapeutics against five specific targets, including those in respiratory indications. This collaboration was the first industry validation of the potential application of Silence Therapeutics' proprietary AtuRNAi molecules and solidified the Company's leadership position in field of RNAi therapeutics.

The Company's AtuRNAi technology also has been sublicensed to Pfizer through Quark's license to Pfizer of the compound RTP-801i-14, for the treatment of age-related macular degeneration (AMD), and a number of other indications. This compound entered the clinic in early 2007. Silence Therapeutics also has licensed to Quark rights to the AtuRNAi structure for its proprietary compound, AKIi-5. This compound is in a Phase I human clinical study for treatment of acute kidney injury.

Silence Therapeutics is based in London, UK, and Berlin, Germany, and is listed on AIM.

# # #